Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting News provided by Share this article Share this article SAN DIEGO, April 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two new data sets from its Phase 3 AMPOWER trial evaluating ® (lactic acid, citric acid, potassium bitartrate) will be presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM). The meeting will be conducted virtually from April 30 - May 2, 2021. "These new data sets provide clinical insights into how women used Phexxi in the AMPOWER clinical trial as well as their feelings about pregnancy, which are both important factors for clinicians to consider when counseling and prescribing Phexxi," said Brandi Howard, PhD, Head of Medical Affairs at Evofem Biosciences.